- Home
- IMSR vs ALT Comparison
IMSR vs ALT Comparison
Compare IMSR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMSR | ALT |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.5M | 573.8M |
| IPO Year | 2024 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IMSR | ALT |
|---|---|---|
| Price | $4.24 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 1.1M | ★ 3.3M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $248,357.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $4.14 | $2.56 |
| 52 Week High | $16.38 | $6.44 |
Technical Indicators
Market Signals| Indicator | IMSR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 51.24 |
| Support Level | N/A | $3.18 |
| Resistance Level | $5.69 | $3.32 |
| Average True Range (ATR) | 0.27 | 0.13 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 4.35 | 33.03 |
Price Performance
Historical ComparisonAbout IMSR Terrestrial Energy Inc.
Terrestrial Energy Inc is a technology company engaged in the development and commercialization of nuclear power plants. The company is focused on its proprietary Integral Molten Salt Reactor (IMSR) technology, a Generation IV reactor design intended to produce reliable, emission-free energy in the form of electricity and high-temperature heat for industrial applications. Its activities mainly involve advancing the design, licensing, and deployment of IMSR plants for commercial energy generation.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.